A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.

Jane KnöchelVijender PandugaKarin NelanderMaria HeijerEva-Lotte LindstedtHodan AliMalin AurellHelena ÖdesjöPablo ForteKat ConnollyHans EricssonIain MacPhee

Published in: British journal of clinical pharmacology (2024)

Atuliflapon is a weak inhibitor of CYP3A4; this was confirmed by the validated PBPK model. This weak inhibition is predicted to have a minor PK effect on CYP3A4 metabolized drugs.

Keyphrases

drug induced
signaling pathway
adverse drug
protein protein
small molecule
binding protein